It has been proposed that extremely low frequency (ELF) magnetic fields may enhance tumorigenesis through a copromotional mechanism. This hypothesis has been further tested using the two-stage model of mouse skin carcinogenesis, i.e. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced promotion of skin tumors in mice initiated by a single subcarcinogenic dose of 7,12-dimethylbenz[a]anthracene. Experimentation described herein utilized the SEN-CAR mouse and examined the effect of a magnetic field on skin tumor promotion induced by three different doses of TPA within its dose-response range, i.e. 0.85, 1.70 or 3.40 nmol, administered twice per week. SENCAR mice (56/treatment group) were exposed to a 60 Hz magnetic field having a flux density of 2 mT for 6 h/day for 5 days/ week and compared with mice exposed to the ambient magnetic field. Tumor incidence and multiplicity were monitored weekly for 23 weeks of TPA promotion. Statistical evaluation of the effects of the magnetic field on tumor incidence and multiplicity did not reveal any statistically significant effects; thus, within the sensitivity limits imposed by the animal model and the exposure parameters employed, no promotional or co-promotional effect of a 2 mT magnetic field on skin tumor development in SENCAR mice could be demonstrated.
Introduction
Although the scientific evidence has been deemed insufficient to support a definitive role for extremely low frequency (ELF) electromagnetic fields in the development of cancer (1,2), several observations have stimulated research on the possible cancer risk. One hypothesis is that exposure to a magnetic field exerts a proliferative effect on cell populations that have been initiated by endogenous or exogenous agents or processes. Studies performed by Stuchly, McLean et al. (3) (4) (5) addressed this hypothesis using the two-stage model of carcinogenesis in mouse skin (6) . They examined the effect of a 2 mT, 60 Hz magnetic field during the promotion phase of two-stage carcinogenesis in SENCAR mice, i.e. mice initiated with a single subcarcinogenic dose of 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with repetitive applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) (3, 5) . No tumors developed in field-or sham-exposed mice that had only been initiated by DMBA, indicating that the magnetic field possessed no direct promoting activity (5) . This was confirmed by Rannug et al. (7) who studied DMBA-initiated NMRI mice exposed to 50 Hz magnetic fields with flux densities of 50 µT and 0.5 mT. Stuchly et al. (3) also investigated the effect of magnetic field exposure as a co-promoter, where a co-promoter in this model is defined as an agent that has no direct tumorpromoting activity, but synergizes with a promoter to enhance papilloma development. In this experiment, DMBA-initiated SENCAR mice were promoted by repetitive, topical applications of TPA (4.9 nmol/week). One group was exposed to the magnetic field during tumor promotion and one group was not. Under these conditions the authors reported a statistically significant increase in tumor incidence and multiplicity at 16-18 weeks of promotion in the field-exposed group, but the difference became non-significant at 23 weeks of promotion. Subsequently, McLean et al. (8) reported the results of three replications of the co-promotion experiment described by Stuchly et al. (3) , also using 4.9 nmol TPA/week. At 23 weeks of TPA promotion only one replication exhibited a statistically significant effect of the magnetic field on tumor incidence and multiplicity; and the direction of that effect was opposite that predicted for co-promotion. Since it cannot be stated with certainty whether the observations reported by Stuchly et al. (3) are indicative of biological activity attributable to the magnetic field or merely reflect usual variation between experimental groups as suggested by McLean et al. (8) , the experiment reported herein was designed to test for any copromotional effect at three different TPA doses that fall within its dose-response range for tumor promotion. As background to these studies, Kavet (9) and McCann et al. (10) have reviewed the cellular and molecular processes that underlie the detection of electromagnetic field-induced effects on carcinogenesis in the SENCAR mouse and other experimental animal models.
Materials and methods

Experimental animals
Female SENCAR mice, 4-6 weeks of age on receipt, were purchased from Harlan/Sprague-Dawley and placed in quarantine for 2 weeks prior to entry onto protocol. During quarantine mice were uniquely identified by tail tattoo. Mice, housed in polycarbonate cages (ഛ5 mice/cage) with corn cob bedding, were fed a Purina certified Rodent Chow and allowed distilled water ad libitum. Rooms housing the mice were maintained at 22 Ϯ 3°C and 55 Ϯ 15% relative humidity and were illuminated with fluorescent lights on a 12 h light/dark cycle. The facility housing the mice was AAALAC accredited and care followed the Guide for the Care and Use of Laboratory Animals (11) .
Initiation/promotion protocol
The dorsoscapular region of the back (~2.5ϫ4 cm) was shaved using an electric shaver in a manner that minimized abrasion or heating of the skin not less than 2 days prior to initiation. Cleaning of the blades was performed using toluene and wiping the blades dry. No oil was used to lubricate the blades. Multiple shavers were used to avoid overheating. Mice were not reshaved during the remainder of the experiment. Mice were initiated by topical application of a subcarcinogenic dose of DMBA (10 nmol in 200 µl acetone) to the shaved skin. DMBA was obtained from Sigma (St Louis, MO) and acetone (spectral grade) was obtained from Baxter Health Care (Muskegon, MI). Prior to initiation, mice exhibiting any general health or skin problems or hair follicles in the active growth phase were excluded from entry onto protocol. Following initiation, mice were housed in disposable cages for 2 weeks to allow removal of residual DMBA that might have become associated with the cage or bedding. During DMBA dosing and for the following 24 h period, mice were held in subdued white light or low-intensity yellow light. After DMBA initiation, mice were randomly assigned to experimental groups using body weight as a blocking variable to assure that there were no statistically significant differences in initial group mean body weights. The weight distribution range of the animals selected for the study was Ͻ20% from the mean body weight of all animals available for the study. Two weeks following DMBA initiation, mice were administered TPA in 200 µl acetone (twice per week: between 0800 and 1200 on Monday and Thursday, or Tuesday and Friday). Dosing with TPA was performed by treatment group, beginning with the acetone controls and proceeding to groups receiving the lowest to the highest doses of TPA. TPA was obtained from L.C. Services (Woburn, MA). During TPA promotion mice were weighed weekly and an assessment of dermal lesions on the dosed skin was performed, also once per week. Using the initiation/promotion protocol described herein and Ͻ25 weeks of TPA promotion, papillomas are essentially the only skin tumors that develop (6); consequently in this report the term 'tumor' and 'papilloma' are equivalent.
Magnetic field exposure facility and engineering
The magnetic field exposures were performed in a system designed for EPRI to accommodate exposures of small experimental animals to 60 Hz sinusoidal magnetic fields linearly polarized in the horizontal direction. This system has been described previously (12) , including documentation of frequency, waveform and environmental parameters. Possible confounding factors, including field uniformity, heating, harmonic distortion and noise, audible hum, electric fields and stray fields, have also been minimized and characterized (12) . The exposure system consists of electrodes on which the animals are housed surrounded by coils to produce horizontal magnetic fields. The coil windings are double-wound (essentially as two separate coils within each coil structure) to allow for null field operation. For the primary co-promotion experiment, one exposure unit had the coil doublets wired in series to generate the 2 mT field; and for the pilot study another unit had the coil doublets connected in reverse to generate a 'null' field. The coils were energized via tuning capacitors by power amplifiers (Techron Model 7570), which were supplied with a sinusoidal signal from an oscillator (Hewlett-Packard, Model 8904A). A computer (Gateway, Model 486/33) with a data acquisition unit and co-processor (Hewlett-Packard, Model 82300C) provided for field control and environmental monitoring of temperature and humidity every 5 min. For the field exposure unit, the computer data acquisition unit sensed the field level and re-adjusted the oscillator output to produce the desired 2 mT field, with constant fields having variations of Ͻ1%. For the null-exposure unit, the computer sensed the current applied to both the field-exposure unit and the null-exposure unit. The oscillator was then adjusted to match the current of the null-exposure unit to the current of the field-exposure unit. In this way, the null field system was energized to yield similar confounding factors (such as identical coil heating) to the field-exposure system, but without the production of a large magnetic field. The geomagnetic (DC) field was measured at 0.051 mT and was essentially the same for all three groups (field-exposed, null field-exposed and ambient field control). The vertical component was 0.047 mT and the horizontal component was 0.019 mT. In the exposure systems, the 60 Hz horizontal exposure field was aligned~20°from magnetic north.
Each exposure system has four tiers for holding mouse cages; each tier can accommodate up to 30 mouse cages utilizing both sides of each electrode with 5 mice/cage. Mice in this study were housed on both sides of the lower three tiers of two systems in the exposure room. The individual cages were rotated within the exposure system each week during change-out procedures. The fields were activated for 6 h/day (between 0900 and 1500), 5 days/week, and all exposure conditions were superimposed over the natural ambient magnetic field of the building (Ͻ0.1 µT). The magnetic field intensity was controled by computer with monitoring every 5 min and daily averages retained.
Ambient control animals were housed in identical cages and systems comparable with those containing the field-exposed and null field-exposed animals. The ambient system was in a separate room in the same facility. Field intensity levels for the ambient controls were monitored at~0.1 µT, with other environmental conditions the same as for the field-exposure/null field-exposure systems (see Table I ).
Pilot experiment
The pilot experiment was designed to permit: (i) the selection of a TPA dose range that would optimize detection of any co-promotional effect produced 1618 by the magnetic field; and (ii) the identification of any environmental effects on skin tumor promotion that could be attributed to housing within an energized exposure unit in which the magnetic field had been nulled. Comparisons were made between mice housed in a null field within the magnetic field exposure facility and mice housed in a separate room within the magnetic field exposure facility and subject to the ambient magnetic field. Mice in the pilot experiment were monitored for skin tumor development for 16 weeks of TPA promotion. Designation of treatment groups is shown in Table II . Each treatment group contained 35 mice. Historical controls have shown minimal skin tumor development for the TPA vehicle control, i.e. acetone; consequently, the vehicle control was omitted from the pilot experiment.
Experimental design: primary experiment
The primary experiment was designed to determine the effect of exposure to a 2 mT (60 Hz) magnetic field on TPA-induced promotion of DMBA-initiated mice and to monitor any such effects at several TPA doses within its doseresponse range. Mice exposed to the 2 mT magnetic field were compared with mice housed in a room separate from the magnetic field exposure unit and subject only to an ambient magnetic field, plus a small stray field from the operating 2 mT system. Mice in the primary experiment were monitored for skin tumor development for 23 weeks of TPA promotion. The designation of treatment groups within each exposure condition is shown in Table III .
Statistical analyses
Statistical analysis of tumor incidence at specific weeks of promotion was performed using chi-square tests (13) . For multiplicity data, mean number of tumors per group was calculated for each treatment group at each week of promotion both by summing the total number of tumors and dividing by the total number of animals evaluated at the given week and by using the number of tumors on each animal and calculating a standard deviation for each treatment group at each week of promotion. Mann-Whitney U-tests were used to compare magnetic field exposures at like TPA treatments. Other statistical treatments of the data were performed and are available on request. All analyses were performed using SPSS (SPSS, Chicago, IL) or Statistica (StatSoft, Tulsa, OK). Statistical significance was considered to be at the 0.05 level or less. Quality assurance Activities conducted during the pilot experiment were conducted in the 'spirit' of the US Environmental Protection Agency's (EPA) 'Good Laboratory Practices'. The primary experiment was conducted in compliance with the 'Good Laboratory Practices' (GLP) regulations of the EPA 40 CFR 792.
Results
Pilot experiment
The pilot experiment was designed to detect any differential effects on skin tumor development attributable to room location or housing within an energized exposure unit in which the magnetic field had been nulled. Tumor development was assessed as a function of tumor incidence and multiplicity over the 16 weeks of TPA promotion. Figure 1 shows the effect of room location (null or ambient magnetic field exposure) on tumor incidence (Panel A) and multiplicity (Panel B). As expected, the effect on tumor development produced by 3.4 nmol TPA was significantly increased over that produced by 0.85 nmol TPA. After 16 weeks of tumor promotion mice housed in the null or ambient field, and administered a promoting dose of 0.85 nmol TPA had 23 and 43% tumor incidences and 1.3 or 2.1 tumors/mouse, respectively. Mice housed in both exposure conditions and administered a promot- ing dose of 3.4 nmol TPA had 94% tumor incidences. Mice housed in the null or ambient field and administered a promoting dose of 3.4 nmol TPA had 8.5 or 7.9 tumors/mouse, respectively. Tumor incidences at weeks 10 and 16 of TPA promotion were chosen for comparison using chi-square analysis. The results of this analysis, shown in Table IV , revealed no statistically significant differences in tumor incidence attributable to room location. Statistical analysis of the data on tumor multiplicity at each TPA dose, using the Mann-Whitney U-test, also revealed no significant differences attributable to room location at 10 or 16 weeks of TPA promotion. The P-values for these comparisons are shown in Table IV .
Preliminary experiment: effect of exposure to a magnetic field (2 mT) on the development of skin tumors
In the primary experiment, mice exposed to the 2 mT (60 Hz) magnetic field were compared with those exposed only to the ambient magnetic field. Based on the results of the pilot experiment, three doses of TPA (0.85, 1.70 and 3.4 nmol), i.e. doses that span the dose-response range for tumor promotion, were utilized in the primary experiment. Figure 2 shows the effect of the 2 mT magnetic field on tumor incidence (Panel A) and tumor multiplicity (Panel B). Control Groups 1 (acetone, 2 mT field) and 2 (acetone, ambient field), i.e. the TPA vehicle controls, developed no tumors. As expected, the uninitiated, TPA-treated control group exposed to the ambient field (Group 9) exhibited very low tumor incidence (12.5% at 23 weeks) and multiplicity (0.13 tumors/mouse at 23 weeks) and was not considered in the statistical analyses that follow. Statistical tests of association were performed to detect treatment-associated effects on tumor incidence. Chi-square tests of magnetic field effects at like TPA treatments revealed no statistically significant differences in tumor incidence associated with the magnetic field exposure at 16 or 23 weeks of promotion (see Table V ). Statistical analysis of tumor multiplicity data using the Mann-Whitney U-test to compare magnetic field exposures at like TPA treatments also revealed no significant differences at 16 or 23 weeks of promotion (Table V) . In summary, no statistically significant effects on tumor incidence or multiplicity were attributable to the 2 mT magnetic field exposure.
Discussion
An important aspect of the current study was to follow closely the experimental design described by Stuchly et al. (3, 4) , but assess tumor development at three different concentrations of TPA within its dose-response range. Differences in the two initiation/promotion protocols were relatively minor and not deemed sufficient to compromise comparison of the two experiments. Several differences, however, require comment. Although purchased from different suppliers, SENCAR mice from both suppliers were derived from the same original stock. Although mice used in the study reported herein were somewhat older on entry onto the TPA promotion protocol, adequate data are available to indicate that no significant differences exist among groups of SENCAR mice entered onto a DMBA/TPA initiation/promotion protocol at 6-10 weeks of age (6, 14) . The most effective tumor promotion in mouse skin occurs when TPA is applied topically twice per week; and most published 1620 studies have utilized such a dosing schedule (6) . To allow comparison with published reports, the study reported herein dosed TPA twice per week, rather than once per week as in the study of Stuchly et al. (3) . The protocol of Stuchly et al.
(3) utilized a diet (Purina 5005) having a higher fat content (11%) than that commonly used in initiation/promotion protocols (6). Dietary fat has been shown to modulate papilloma development (15, 16) , with a high fat content increasing the incidence and multiplicity of papillomas. The protocol described herein utilized the Purina 5015 diet having a 4.5% fat content. It was initially demonstrated in a pilot experiment that TPA doses within the range of 0.85-3.4 nmol were appropriate for the primary study. Secondly, comparisons made between mice housed in a room separated from the magnetic field exposure unit and exposed only to an ambient magnetic field and mice housed in an energized exposure unit in which the magnetic field had been nulled revealed no statistically significant room location-related effects on the development of skin tumors in TPA-promoted mice. The pilot experiment illustrates an important point in interpreting tumor development data from this and other experimental animal models. Mice treated with 0.85 nmol TPA in the ambient field exhibited slightly higher tumor incidences and multiplicities after 9-10 weeks of promotion. In groups treated with 3.4 nmol TPA, null field-exposed mice exhibited slightly higher tumor incidences and multiplicities at 6-15 weeks of promotion. Since the differential room location-related tumor responses were not consistent at the two doses nor were they statistically significant, these differences can be attributed to experimental variation. This result emphasizes the fact that a conclusive co-promotional effect of magnetic field exposure can be demonstrated only by a consistent effect observed at several different doses of the tumor promoter that fall within an appropriate doseresponse range.
The primary experiment, which utilized three different doses of TPA within the dose-response range for the promotion of skin tumors in DMBA-initiated SENCAR mice (plus the vehicle controls), was designed to optimize conditions for the detection of a co-promotional effect of a 2 mT magnetic field. Neither group 1 or 2 developed skin tumors, indicating that the magnetic field possessed no direct tumor-promoting activity on mouse skin. This observation is consistent with those of McLean et al. (5) Rannug et al. (7) . Statistical analyses (see Table V ) of effects on tumor incidence and multiplicity did not reveal any statistically significant effects; thus, within the sensitivity limits imposed by the animal model and the exposure parameters employed, no co-promotional effect of a 2 mT magnetic field on tumor development could be demonstrated. The primary experiment was concluded at 23 weeks of tumor promotion when progression of papillomas to carcinomas is minimal (6) . This time point was chosen based on the following rationale: first, the end-point of tumor promotion is the papilloma (6) , and second, by definition any co-promotional effect would be observed on papilloma development (6) . Consequently, this experiment does not address the potential effect of magnetic field exposure on other aspects of the carcinogenic process. In this regard, McLean et al. reported a study wherein DMBA/TPA-induced skin tumor development in SENCAR mice was monitored for 29 weeks following 23 weeks of TPA promotion (17) . They reported that exposure to a 2 mT magnetic field for the entire 52-week period increased the conversion of papillomas to carcinomas. This preliminary report (17) should be interpreted with caution, since the conclusion is based on comparison of a group of mice that had five more animals (field-exposed group) with papillomas (15 out of 48), compared with the controls (sham exposed) that had 10 out of 48 mice with papillomas. Thus, five additional mice were at risk in the field-exposed group. In addition, this experiment has not been repeated. This latter point is particularly important since normal variability between experiments is greatest when using the lowest doses of promoter and when groups of mice have low incidences of tumors in the SENCAR model. This is due to the outbred nature of the SENCAR mice. Therefore, biological significance as demonstrated in replicated experiments is more conclusive than statistical significance in a single experiment.
In summary, within the sensitivity limits imposed by the animal model and the exposure parameters employed, no promotional or co-promotional effects of a 2 mT magnetic field on skin tumor development in SENCAR mice could be demonstrated.
